Experienced in Diffuse Large B-Cell Lymphoma (DLBCL)

Dr. Bradley T. Sumrall

Hematology | Oncology
Piedmont Healthcare
Central Georgia Cancer Care
5430 Bowman Road, 
Macon, GA 
Accepting New Patients
Offers Telehealth

Experienced in Diffuse Large B-Cell Lymphoma (DLBCL)
Piedmont Healthcare
Central Georgia Cancer Care
5430 Bowman Road, 
Macon, GA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Bradley Sumrall is a Hematologist and an Oncologist in Macon, Georgia. Dr. Sumrall is rated as an Experienced provider by MediFind in the treatment of Diffuse Large B-Cell Lymphoma (DLBCL). His top areas of expertise are Lung Cancer, Pleuropulmonary Blastoma, Thrombocytopenia, and Idiopathic Neutropenia. Dr. Sumrall is currently accepting new patients.

His clinical research consists of co-authoring 5 peer reviewed articles and participating in 14 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has participated in 1 clinical trial in the study of Diffuse Large B-Cell Lymphoma (DLBCL).

Graduate Institution
University Of Georgia, 1998
Residency
MUSC Medical Univ of South Carolina, Internal Medicine, 2006
Specialties
Hematology
Oncology
Licenses
Specialist in GA
Board Certifications
American Board Of Internal Medicine
Fellowships
Ochsner Medical Institution, Medical Oncology, 2013
Hospital Affiliations
Coliseum Medical Centers, Llc, Dba
Atrium Health Navicent The Medical Center
Piedmont Macon North Hospital
Houston Healthcare
Northside Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Alliant Health
  • HMO
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
CareSource
  • HMO
Cigna
  • EPO
  • HMO
  • PPO
Clover Health
  • INSURANCE PLAN
  • MEDICARE MAPD
EmblemHealth
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Oscar
  • EPO
  • HMO
  • PPO
Simply Healthcare
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 15 Less Insurance Carriers -

Locations

Central Georgia Cancer Care
5430 Bowman Road, Macon, GA 31210
Call: 478-743-7068

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


13 Clinical Trials

Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Enrollment Status: Active_not_recruiting
Publish Date: December 17, 2025
Intervention Type: Other, Procedure, Biological, Drug
Study Phase: Not Applicable
Randomized Study of Erlotinib Vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Randomized Study of Erlotinib Vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Enrollment Status: Active_not_recruiting
Publish Date: December 04, 2025
Intervention Type: Other, Drug
Study Drug: Erlotinib Hydrochloride
Study Phase: Phase 3
A Randomized Phase III Trial of Endocrine Therapy Plus Entinostat/Placebo in Patients With Hormone Receptor-Positive Advanced Breast Cancer
A Randomized Phase III Trial of Endocrine Therapy Plus Entinostat/Placebo in Patients With Hormone Receptor-Positive Advanced Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: December 01, 2025
Intervention Type: Other, Procedure, Drug
Study Drugs: Entinostat, Exemestane, Goserelin, Goserelin Acetate
Study Phase: Phase 3
A Randomized Phase III Post-operative Trial of Platinum Based Chemotherapy vs. Capecitabine in Patients With Residual Triple-Negative Basal-Like Breast Cancer Following Neoadjuvant Chemotherapy
A Randomized Phase III Post-operative Trial of Platinum Based Chemotherapy vs. Capecitabine in Patients With Residual Triple-Negative Basal-Like Breast Cancer Following Neoadjuvant Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: November 24, 2025
Intervention Type: Drug
Study Drugs: Capecitabine, Carboplatin, Cisplatin
Study Phase: Phase 3
Molecular Analysis for Therapy Choice (MATCH)
Molecular Analysis for Therapy Choice (MATCH)
Enrollment Status: Active_not_recruiting
Publish Date: November 17, 2025
Intervention Type: Procedure, Drug, Other, Biological
Study Drugs: Adavosertib, Afatinib, Binimetinib, Capivasertib, Copanlisib, Crizotinib, Dabrafenib, Dasatinib, Defactinib, Erdafitinib, FGFR Inhibitor AZD4547, Ipatasertib, Larotrectinib, Nivolumab, Osimertinib, Palbociclib, Pertuzumab, PI3K-Beta Inhibitor GSK2636771, Sapanisertib, Sunitinib, Taselisib, Trametinib, Trastuzumab, Ulixertinib, Vismodegib
Study Phase: Phase 2
eMonarcHER: A Randomized, Double Blind, Placebo-Controlled Phase 3 Study of Abemaciclib Plus Standard Adjuvant Endocrine Therapy in Participants With High-Risk, Node-Positive, HR+, HER2+ Early Breast Cancer Who Have Completed Adjuvant HER2-Targeted Therapy
eMonarcHER: A Randomized, Double Blind, Placebo-Controlled Phase 3 Study of Abemaciclib Plus Standard Adjuvant Endocrine Therapy in Participants With High-Risk, Node-Positive, HR+, HER2+ Early Breast Cancer Who Have Completed Adjuvant HER2-Targeted Therapy
Enrollment Status: Terminated
Publish Date: July 15, 2025
Intervention Type: Drug
Study Drugs: Abemaciclib, Standard Adjuvant Endocrine Therapy
Study Phase: Phase 3
CYCLONE 3: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Abemaciclib in Combination With Abiraterone Plus Prednisone in Men With High-Risk Metastatic Hormone-Sensitive Prostate Cancer
CYCLONE 3: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Abemaciclib in Combination With Abiraterone Plus Prednisone in Men With High-Risk Metastatic Hormone-Sensitive Prostate Cancer
Enrollment Status: Active_not_recruiting
Publish Date: June 27, 2025
Intervention Type: Drug
Study Phase: Phase 3
A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone in Patients With High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer
A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone in Patients With High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: April 20, 2025
Intervention Type: Drug
Study Drugs: Abemaciclib, Standard Adjuvant Endocrine Therapy
Study Phase: Phase 3
postMONARCH: A Randomized, Double Blind, Placebo-Controlled, Phase 3 Study to Compare the Efficacy of Abemaciclib Plus Fulvestrant to Placebo Plus Fulvestrant in Participants With HR+, HER2-, Advanced or Metastatic Breast Cancer Following Progression on a CDK4 & 6 Inhibitor and Endocrine Therapy
postMONARCH: A Randomized, Double Blind, Placebo-Controlled, Phase 3 Study to Compare the Efficacy of Abemaciclib Plus Fulvestrant to Placebo Plus Fulvestrant in Participants With HR+, HER2-, Advanced or Metastatic Breast Cancer Following Progression on a CDK4 & 6 Inhibitor and Endocrine Therapy
Enrollment Status: Active_not_recruiting
Publish Date: April 18, 2025
Intervention Type: Drug
Study Drugs: Abemaciclib, Fulvestrant
Study Phase: Phase 3
Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer
Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: January 13, 2025
Intervention Type: Other
Study Phase: Phase 3
Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib vs Placebo in Combination With Capecitabine and Trastuzumab in Patients With Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Carcinoma
Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib vs Placebo in Combination With Capecitabine and Trastuzumab in Patients With Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Carcinoma
Enrollment Status: Completed
Publish Date: August 14, 2023
Intervention Type: Drug
Study Drugs: tucatinib, capecitabine, trastuzumab
Study Phase: Phase 2
A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial
A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial
Enrollment Status: Terminated
Publish Date: April 05, 2023
Intervention Type: Other, Drug
Study Drug: Aspirin
Study Phase: Phase 3
An Open Label Phase 2 Study of Denintuzumab Mafodotin (SGN-CD19A) in Combination With RCHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone) or RCHP (Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone) Compared With RCHOP Alone as Frontline Therapy in Patients With Diffuse Large B-cell Lymphoma (DLBCL) or Follicular Lymphoma (FL) Grade 3b
An Open Label Phase 2 Study of Denintuzumab Mafodotin (SGN-CD19A) in Combination With RCHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone) or RCHP (Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone) Compared With RCHOP Alone as Frontline Therapy in Patients With Diffuse Large B-cell Lymphoma (DLBCL) or Follicular Lymphoma (FL) Grade 3b
Enrollment Status: Terminated
Publish Date: March 11, 2019
Intervention Type: Drug
Study Phase: Phase 2
View 12 Less Clinical Trials

5 Total Publications

Milademetan in advanced solid tumors with MDM2 amplification and wild-type TP53: pre-clinical and phase 2 clinical trial results.
Milademetan in advanced solid tumors with MDM2 amplification and wild-type TP53: pre-clinical and phase 2 clinical trial results.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: March 06, 2025
View All 5 Publications
Similar Doctors
Damien Hansra
Advanced in Diffuse Large B-Cell Lymphoma (DLBCL)
Dr. Damien Hansra
Oncology | Hematology
Advanced in Diffuse Large B-Cell Lymphoma (DLBCL)
Dr. Damien Hansra
Oncology | Hematology

Piedmont Physicians Medical Oncology Fayetteville

1267 Highway 54 W Ste 3100, 
Fayetteville, GA 
 (67.0 miles away)
770-719-7365
Languages Spoken:
English, French, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Damien Hansra, M.D., earned his medical degree from University of Miami and completed his residency and fellowship at University of Miami - Jackson Memorial Hospital. He is board certified in Hematology, Medical Oncology and Internal Medicine. He has been practicing medicine for over 13 years. Prior to joining Piedmont, Dr. Hansra was at the Cancer Treatment Centers of America. He specializes in Hematology and Medical Oncology and has a special interest in Wellness and Obesity.Read his article in the Atlanta Journal-Constitution,Are you at risk for breast cancer? Risk factors, screenings, symptoms and treatments to know.In his spare time, he enjoys spending time with family, exercising (running, biking, walking dogs), cooking, travel.Dr. Hansra is accepting new patients and welcomes most major insurance plans. Dr. Hansra is rated as a Distinguished provider by MediFind in the treatment of Diffuse Large B-Cell Lymphoma (DLBCL). His top areas of expertise are Pleuropulmonary Blastoma, Breast Cancer, Chronic B-Cell Leukemia (CBCL), and Angiosarcoma.

Premila Malhotra
Advanced in Diffuse Large B-Cell Lymphoma (DLBCL)
Dr. Premila Malhotra
Hematology | Oncology
Advanced in Diffuse Large B-Cell Lymphoma (DLBCL)
Dr. Premila Malhotra
Hematology | Oncology

Georgia Cancer Specialists

308 Coliseum Drive, Suite 120, 
Macon, GA 
 (1.3 miles away)
478-745-6130
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Premila Malhotra is a Hematologist and an Oncologist in Macon, Georgia. Dr. Malhotra is rated as a Distinguished provider by MediFind in the treatment of Diffuse Large B-Cell Lymphoma (DLBCL). Her top areas of expertise are Colorectal Cancer, Familial Colorectal Cancer, Thrombocytopenia, and Pleuropulmonary Blastoma. Dr. Malhotra is currently accepting new patients.

Vasileios J. Assikis
Advanced in Diffuse Large B-Cell Lymphoma (DLBCL)
Dr. Vasileios J. Assikis
Oncology | Hematology
Advanced in Diffuse Large B-Cell Lymphoma (DLBCL)
Dr. Vasileios J. Assikis
Oncology | Hematology

Piedmont Cancer Institute, PC

1267 Highway 54 West, Suite 4200, 
Fayetteville, GA 
 (67.0 miles away)
678-829-1060
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Vasileios Assikis is a Hematologist and an Oncologist in Fayetteville, Georgia. Dr. Assikis is rated as a Distinguished provider by MediFind in the treatment of Diffuse Large B-Cell Lymphoma (DLBCL). His top areas of expertise are Clear Cell Sarcoma, WT1-Related Wilms Tumor Syndromes, Adult Soft Tissue Sarcoma, and Renal Cell Carcinoma (RCC). Dr. Assikis is currently accepting new patients.

VIEW MORE DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Sumrall's expertise for a condition
ConditionClose
    • Distinguished
    • Acute Myeloblastic Leukemia without Maturation
      Dr. Sumrall is
      Distinguished
      . Learn about Acute Myeloblastic Leukemia without Maturation.
      See more Acute Myeloblastic Leukemia without Maturation experts
    • Acute Myeloid Leukemia (AML)
      Dr. Sumrall is
      Distinguished
      . Learn about Acute Myeloid Leukemia (AML).
      See more Acute Myeloid Leukemia (AML) experts
    • Agranulocytosis
      Dr. Sumrall is
      Distinguished
      . Learn about Agranulocytosis.
      See more Agranulocytosis experts
    • Breast Cancer
      Dr. Sumrall is
      Distinguished
      . Learn about Breast Cancer.
      See more Breast Cancer experts
    • Chronic Familial Neutropenia
      Dr. Sumrall is
      Distinguished
      . Learn about Chronic Familial Neutropenia.
      See more Chronic Familial Neutropenia experts
    • Colorectal Cancer
      Dr. Sumrall is
      Distinguished
      . Learn about Colorectal Cancer.
      See more Colorectal Cancer experts
    View All 16 Distinguished Conditions
    • Advanced
    • Acute Myeloblastic Leukemia with Maturation
      Dr. Sumrall is
      Advanced
      . Learn about Acute Myeloblastic Leukemia with Maturation.
      See more Acute Myeloblastic Leukemia with Maturation experts
    • Adult Immune Thrombocytopenia
      Dr. Sumrall is
      Advanced
      . Learn about Adult Immune Thrombocytopenia.
      See more Adult Immune Thrombocytopenia experts
    • Adult Soft Tissue Sarcoma
      Dr. Sumrall is
      Advanced
      . Learn about Adult Soft Tissue Sarcoma.
      See more Adult Soft Tissue Sarcoma experts
    • ALK-Positive Non-Small Cell Lung Cancer
      Dr. Sumrall is
      Advanced
      . Learn about ALK-Positive Non-Small Cell Lung Cancer.
      See more ALK-Positive Non-Small Cell Lung Cancer experts
    • Anemia
      Dr. Sumrall is
      Advanced
      . Learn about Anemia.
      See more Anemia experts
    • Angiosarcoma
      Dr. Sumrall is
      Advanced
      . Learn about Angiosarcoma.
      See more Angiosarcoma experts
    View All 53 Advanced Conditions
    • Experienced
    • Acute Eosinophilic Pneumonia
      Dr. Sumrall is
      Experienced
      . Learn about Acute Eosinophilic Pneumonia.
      See more Acute Eosinophilic Pneumonia experts
    • Adrenal Cancer
      Dr. Sumrall is
      Experienced
      . Learn about Adrenal Cancer.
      See more Adrenal Cancer experts
    • Alpha Thalassemia
      Dr. Sumrall is
      Experienced
      . Learn about Alpha Thalassemia.
      See more Alpha Thalassemia experts
    • Alpha Thalassemia X-Linked Intellectual Disability Syndrome
      Dr. Sumrall is
      Experienced
      . Learn about Alpha Thalassemia X-Linked Intellectual Disability Syndrome.
      See more Alpha Thalassemia X-Linked Intellectual Disability Syndrome experts
    • Ampullary Cancer
      Dr. Sumrall is
      Experienced
      . Learn about Ampullary Cancer.
      See more Ampullary Cancer experts
    • Anal Cancer
      Dr. Sumrall is
      Experienced
      . Learn about Anal Cancer.
      See more Anal Cancer experts
    View All 91 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile
    For Patients
    • Our Story
    • How MediFind Works
    • Conditions A-Z
    • Doctor Directory
    • Symptoms Directory
    • Procedures Directory
    • Treatment Directory
    • Drug Directory
    • Infusion Center Finder
    • FAQ
    • Contact Us
    For Providers and Practices
    • Claim Your Profile
    • Newsroom
    Business Solutions
    • Provider
    • Network Solutions
    Additional Resources
    • Consumer Health Data Privacy Policy
    • Privacy Policy
    • Terms of Use
    • Advertising Policy
    • Content Policy
    Subscribe to our newsletter

    Sign up to stay informed about MediFind and get wellness sent your way.

    Close

      By subscribing, I agree to MediFind's Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.

      Bullet PinMediFind
      Follow us on
      This information is not intended as a substitute for informed medical advice. You should work with a licensed professional to diagnose and treat health conditions. We let the data speak for itself, MediFind does not endorse any healthcare providers.
      © 2026 All Rights Reserved

      Request an Appointment

      If you are experiencing a medical emergency, call 9-1-1.

      MediFind will contact the provider for your appointment request. You’ll receive status updates by email. Your provider or MediFind will reach out to you directly by phone or email to schedule your appointment or request additional information.

      Patient Details

      This information is for the patient who will be seen at the appointment.

        Close

        Returning patient? Use your address on file with the provider.

        Insurance Details

        Please provide information of the primary insurance holder as the practice may require this information to schedule.

        Insurance Provider *
        Insurance ProviderClose

        Appointments Details

        Let’s get more information about your appointment.

                0 / 1000
                0 / 1000
                By pressing the Submit button you are agreeing to MediFind’s Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.